Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs

Although the sodium channel blocker mexiletine is considered the first-line drug in myotonia, some patients experiment adverse effects, while others do not gain any benefit. Other antimyotonic drugs are thus needed to offer mexiletine alternatives. In the present study, we used a previously-validate...

Descripción completa

Detalles Bibliográficos
Autores principales: Desaphy, Jean-François, Carbonara, Roberta, Costanza, Teresa, Conte Camerino, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2014
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004800/
https://www.ncbi.nlm.nih.gov/pubmed/24613829
http://dx.doi.org/10.1016/j.expneurol.2014.02.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004800/
https://www.ncbi.nlm.nih.gov/pubmed/24613829
http://dx.doi.org/10.1016/j.expneurol.2014.02.023

Ejemplares similares